MLCK inhibitor peptide 18 is a cell-permeable inhibitor of myosin light chain kinase (MLCK; IC50 = 50 nM), and displays 4000-fold selectivity over cam kinase ii and does not inhibit PKA. It prevents defects in transepithelial barrier resistance induced by bacteria or TNF-α plus IFN-γ. MLCK inhibitor peptide 18 prevents sperm chromatin-induced cortical reorganization in mouse oocytes and decreases phagocytosis of C3bi-opsonized and non-opsonized myelin by primary mouse microglia.
CAT No: R0854
CAS No:224579-74-2
Synonyms/Alias:MLCK inhibitor peptide 18;224579-74-2;Myosin Light Chain Kinase Inhibitor Peptide 18;CHEMBL443574;peptide 18;H-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-Arg-Lys-NH2;MLCK Inhibitor Peptide-18;GTPL9351;GLXC-15538;ZIA57974;R-K-K-Y-K-Y-R-R-K-NH2;BDBM50074638;AKOS024456829;DA-65540;G13301;
1. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum
4. Peptides as Active Ingredients: A Challenge for Cosmeceutical Industry
5. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.